Humacyte Historical Financial Ratios

HUMAW Stock  USD 1.50  0.09  5.66%   
Humacyte is recently reporting on over 81 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 22.77 or Days Sales Outstanding of 7.9 will help investors to properly organize and evaluate Humacyte financial condition quickly.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

About Humacyte Financial Ratios Analysis

HumacyteFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Humacyte investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Humacyte financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Humacyte history.

Humacyte Financial Ratios Chart

At this time, Humacyte's PTB Ratio is fairly stable compared to the past year. Book Value Per Share is likely to climb to 0.14 in 2024, whereas Days Sales Outstanding is likely to drop 7.90 in 2024.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Cash Conversion Cycle

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Humacyte stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Humacyte sales, a figure that is much harder to manipulate than other Humacyte multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Free Cash Flow Per Share

The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.

Average Inventory

The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.
Most ratios from Humacyte's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Humacyte current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.At this time, Humacyte's PTB Ratio is fairly stable compared to the past year. Book Value Per Share is likely to climb to 0.14 in 2024, whereas Days Sales Outstanding is likely to drop 7.90 in 2024.
 2021 2022 2023 2024 (projected)
Graham Number8.043.991.781.69
Receivables Turnover7.1850.4845.4447.71

Humacyte fundamentals Correlations

0.33-0.21-0.30.790.68-0.880.330.940.730.440.320.88-0.47-0.910.32-0.87-0.34-0.630.030.88-0.730.770.62-0.18-0.22
0.33-0.71-0.060.80.75-0.411.00.320.75-0.470.940.48-0.83-0.310.94-0.3-0.79-0.9-0.920.41-0.87-0.07-0.16-0.98-0.97
-0.21-0.710.28-0.52-0.730.48-0.71-0.34-0.73-0.05-0.69-0.410.930.36-0.690.290.980.540.57-0.470.560.45-0.260.670.73
-0.3-0.060.280.010.050.66-0.06-0.6-0.04-0.18-0.120.060.140.64-0.120.710.36-0.08-0.01-0.660.050.0-0.040.030.22
0.790.8-0.520.010.93-0.680.80.670.940.00.740.9-0.8-0.640.74-0.58-0.64-0.97-0.520.68-0.990.440.34-0.69-0.67
0.680.75-0.730.050.93-0.630.750.591.00.170.690.9-0.92-0.580.69-0.47-0.78-0.89-0.450.63-0.910.20.52-0.64-0.63
-0.88-0.410.480.66-0.68-0.63-0.41-0.98-0.7-0.42-0.41-0.710.60.99-0.410.970.60.540.09-1.00.67-0.46-0.530.280.4
0.331.0-0.71-0.060.80.75-0.410.320.75-0.470.940.48-0.83-0.310.94-0.3-0.79-0.9-0.920.41-0.87-0.07-0.16-0.98-0.97
0.940.32-0.34-0.60.670.59-0.980.320.660.460.340.73-0.5-0.990.34-0.97-0.47-0.510.010.98-0.640.590.56-0.19-0.29
0.730.75-0.73-0.040.941.0-0.70.750.660.20.690.91-0.92-0.650.69-0.55-0.79-0.88-0.440.7-0.920.240.53-0.63-0.63
0.44-0.47-0.05-0.180.00.17-0.42-0.470.460.2-0.470.42-0.05-0.48-0.47-0.380.00.220.760.410.110.280.930.60.53
0.320.94-0.69-0.120.740.69-0.410.940.340.69-0.470.41-0.79-0.291.0-0.28-0.77-0.81-0.90.41-0.78-0.1-0.18-0.95-0.93
0.880.48-0.410.060.90.9-0.710.480.730.910.420.41-0.68-0.710.41-0.61-0.48-0.78-0.10.71-0.830.570.71-0.33-0.31
-0.47-0.830.930.14-0.8-0.920.6-0.83-0.5-0.92-0.05-0.79-0.680.5-0.790.410.950.790.6-0.590.810.13-0.360.750.78
-0.91-0.310.360.64-0.64-0.580.99-0.31-0.99-0.65-0.48-0.29-0.710.5-0.290.980.490.49-0.03-0.990.62-0.56-0.570.170.29
0.320.94-0.69-0.120.740.69-0.410.940.340.69-0.471.00.41-0.79-0.29-0.28-0.77-0.81-0.90.41-0.78-0.1-0.18-0.95-0.93
-0.87-0.30.290.71-0.58-0.470.97-0.3-0.97-0.55-0.38-0.28-0.610.410.98-0.280.440.450.0-0.970.58-0.57-0.440.180.31
-0.34-0.790.980.36-0.64-0.780.6-0.79-0.47-0.790.0-0.77-0.480.950.49-0.770.440.650.62-0.60.680.3-0.230.740.81
-0.63-0.90.54-0.08-0.97-0.890.54-0.9-0.51-0.880.22-0.81-0.780.790.49-0.810.450.650.68-0.540.99-0.32-0.140.820.78
0.03-0.920.57-0.01-0.52-0.450.09-0.920.01-0.440.76-0.9-0.10.6-0.03-0.90.00.620.68-0.090.610.30.510.970.94
0.880.41-0.47-0.660.680.63-1.00.410.980.70.410.410.71-0.59-0.990.41-0.97-0.6-0.54-0.09-0.670.460.53-0.28-0.4
-0.73-0.870.560.05-0.99-0.910.67-0.87-0.64-0.920.11-0.78-0.830.810.62-0.780.580.680.990.61-0.67-0.38-0.230.770.76
0.77-0.070.450.00.440.2-0.46-0.070.590.240.28-0.10.570.13-0.56-0.1-0.570.3-0.320.30.46-0.380.350.180.2
0.62-0.16-0.26-0.040.340.52-0.53-0.160.560.530.93-0.180.71-0.36-0.57-0.18-0.44-0.23-0.140.510.53-0.230.350.310.27
-0.18-0.980.670.03-0.69-0.640.28-0.98-0.19-0.630.6-0.95-0.330.750.17-0.950.180.740.820.97-0.280.770.180.310.98
-0.22-0.970.730.22-0.67-0.630.4-0.97-0.29-0.630.53-0.93-0.310.780.29-0.930.310.810.780.94-0.40.760.20.270.98
Click cells to compare fundamentals

Humacyte Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.